| Literature DB >> 31720401 |
Kentaro Wakamatsu1, Nobuhiko Nagata2, Hiroyuki Kumazoe3, Satosi Honjyo4, Makiko Hara1, Aiko Nagaoka1, Naotaka Noda1, Kouji Okamura1, Kenji Kawatoko1, Mizuko Ose1, Erika Yamada1, Takashi Akasaki1, Sanae Maki1, Shinji Ise1, Miiru Izumi1, Masayuki Kawasaki1.
Abstract
BACKGROUND ANDEntities:
Keywords: ARDS; Miliary tuberculosis; Old age; Prognosis
Year: 2018 PMID: 31720401 PMCID: PMC6830168 DOI: 10.1016/j.jctube.2018.07.001
Source DB: PubMed Journal: J Clin Tuberc Other Mycobact Dis ISSN: 2405-5794
Fig. 1Chest computed tomographic scans showed three patterns: only diffuse nodules exhibiting a random distribution (A); diffuse nodules exhibiting a random distribution with infiltrations (B); and diffuse nodules exhibiting a random distribution with ground glass opacities (C).
Comparisons of demographic, clinical, and laboratory characteristics between patients with miliary tuberculosis who died within three months (non-survivors) and who survived longer than three months (survivors).
| Parameters | Survivors ( | Non-survivors ( | Crude odds ratio | 95%CI | Adjusted* odds ratio | 95%CI | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lower limit | Upper limit | Lower limit | Upper limit | ||||||||
| Age (years) | ≤72 | 13 | 0 | 3.88† | 1.58 | 9.55 | 8.14† | 1.98 | 33.48 | ||
| 73–78 | 11 | 0 | |||||||||
| 79–85 | 15 | 6 | |||||||||
| ≥86 | 14 | 9 | |||||||||
| Sex | Female | 37 | 13 | 1.00 | Reference | 1.00 | Reference | ||||
| Male | 16 | 2 | 0.36 | 0.07 | 1.76 | 0.206 | 0.43 | 0.07 | 2.60 | 0.357 | |
| Smoking history | Absence | 45 | 11 | 1.00 | Reference | 0.465 | 1.00 | Reference | 0.287 | ||
| Presence | 7 | 3 | 1.75 | 0.39 | 7.89 | 2.75 | 0.43 | 17.72 | |||
| Unknown | 1 | 1 | – | – | – | – | – | – | – | – | |
| Alcohol intake | Absence | 46 | 12 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 6 | 2 | 1.28 | 0.23 | 7.15 | 0.780 | 1.13 | 0.15 | 8.52 | 0.904 | |
| Unknown | 1 | 1 | – | – | – | – | – | – | – | – | |
| PS | 1 | 8 | 0 | 1.00 | Reference | 1.00 | Reference | ||||
| 2 | 10 | 1 | |||||||||
| 3 | 15 | 3 | 3.60 | 0.34 | 38.30 | 0.288 | 3.75 | 0.29 | 49.03 | 0.313 | |
| 4 | 20 | 11 | 9.90 | 1.16 | 84.47 | 0.036 | 7.64 | 0.71 | 82.15 | 0.093 | |
| Smear | Negative | 17 | 2 | 1.00 | Reference | 1.00 | Reference | ||||
| Positive | 36 | 13 | 3.07 | 0.62 | 15.15 | 0.169 | 1.81 | 0.30 | 10.99 | 0.518 | |
| Drug sensitivity pattern | 0** | 37 | 12 | – | – | – | 0.468 (Fisher's exact test) | – | – | – | – |
| 1*** | 7 | 0 | – | – | – | – | – | – | |||
| 2**** | 1 | 0 | – | – | – | – | – | – | |||
| N/A | 8 | 3 | – | – | – | – | – | – | – | – | |
| PaO2/FiO2ratio | 52.9 - | 13 | 7 | 1.00 | Reference | 1.00 | Reference | ||||
| 309 - | 26 | 5 | 0.36 | 0.09 | 1.35 | 0.128 | 0.85 | 0.06 | 11.15 | 0.900 | |
| 357 - | 2 | 0 | 0.40 | 0.08 | 1.87 | 0.244 | 1.61 | 0.10 | 25.16 | 0.736 | |
| 378 - | 12 | 3 | |||||||||
| PCR | Negative | 14 | 2 | 1.00 | Reference | 1.00 | Reference | ||||
| Positive | 39 | 11 | 1.97 | 0.39 | 10.03 | 0.412 | 0.97 | 0.14 | 6.69 | 0.979 | |
| N/A | 0 | 2 | – | – | – | – | – | – | – | – | |
| MGIT | Negative | 8 | 0 | – | – | – | 0.188 (Fisher's exact test ) | – | – | – | – |
| Positive | 36 | 11 | – | – | – | – | – | – | |||
| N/A | 9 | 4 | – | – | – | – | – | – | – | – | |
| Culture | Negative | 10 | 1 | 1.00 | Reference | 1.00 | Reference | ||||
| Positive | 43 | 14 | 3.26 | 0.38 | 27.74 | 0.280 | 1.56 | 0.14 | 17.71 | 0.719 | |
| ARDS onset | Absence | 46 | 9 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 7 | 6 | 4.38 | 1.19 | 16.13 | 0.026 | 15.34 | 2.13 | 110.25 | 0.007 | |
| Underlying disease | Absence | 11 | 0 | – | – | – | 0.105 (Fisher's exact test ) | – | – | – | – |
| Presence | 42 | 15 | – | – | – | – | – | – | |||
| Heart disease | Absence | 44 | 9 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 9 | 6 | 3.26 | 0.93 | 11.46 | 0.066 | 2.64 | 0.61 | 11.48 | 0.195 | |
| Diabetes | Absence | 39 | 11 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 14 | 4 | 1.01 | 0.28 | 3.71 | 0.984 | 1.83 | 0.36 | 9.26 | 0.464 | |
| Dementia | Absence | 41 | 11 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 12 | 4 | 1.24 | 0.33 | 4.62 | 0.746 | 0.30 | 0.05 | 1.78 | 0.187 | |
| Malignancy | Absence | 44 | 13 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 9 | 2 | 0.75 | 0.14 | 3.93 | 0.735 | 8.09 | 0.47 | 139.67 | 0.150 | |
| Cerebrovascular disease | Absence | 42 | 14 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 11 | 1 | 0.27 | 0.03 | 2.31 | 0.233 | 0.20 | 0.02 | 1.98 | 0.171 | |
| Renal disease | Absence | 50 | 11 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 3 | 4 | 6.06 | 1.18 | 31.03 | 0.031 | 4.93 | 0.62 | 39.43 | 0.132 | |
| Liver disease | Absence | 49 | 12 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 4 | 3 | 3.06 | 0.60 | 15.55 | 0.177 | 12.61 | 1.03 | 154.21 | 0.047 | |
| Connective tissue disease with steroid treatment | Absence | 45 | 14 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 8 | 1 | 0.40 | 0.05 | 3.50 | 0.409 | 0.58 | 0.05 | 6.25 | 0.657 | |
| Aneurysm | Absence | 50 | 15 | – | – | – | 1.000 (Fisher's exact test ) | – | – | – | – |
| Presence | 3 | 0 | – | – | – | – | – | – | |||
| Neuromuscular disease | Absence | 50 | 15 | – | – | – | 1.000 (Fisher's exact test) | – | – | – | – |
| Presence | 3 | 0 | – | – | – | – | – | – | |||
| Symptoms | |||||||||||
| Fever (≥38 °C) | Absence | 13 | 4 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 40 | 11 | 0.89 | 0.24 | 3.29 | 0.866 | 1.25 | 0.25 | 6.23 | 0.785 | |
| Cough | Absence | 36 | 13 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 17 | 2 | 0.33 | 0.07 | 1.61 | 0.169 | 0.58 | 0.09 | 3.66 | 0.562 | |
| Sputum | Absence | 41 | 13 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 12 | 2 | 0.53 | 0.10 | 2.66 | 0.437 | 0.88 | 0.13 | 6.05 | 0.895 | |
| Dyspnea | Absence | 40 | 8 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 13 | 7 | 2.69 | 0.82 | 8.87 | 0.103 | 1.47 | 0.29 | 7.35 | 0.637 | |
| Loss of appetite | Absence | 22 | 2 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 31 | 13 | 4.61 | 0.94 | 22.53 | 0.059 | 4.19 | 0.70 | 24.96 | 0.116 | |
| General malaise | Absence | 20 | 3 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 33 | 12 | 2.42 | 0.61 | 9.65 | 0.209 | 2.07 | 0.42 | 10.05 | 0.369 | |
| Consciousness disturbance | Absence | 48 | 12 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 5 | 3 | 2.40 | 0.50 | 11.48 | 0.273 | 9.25 | 0.82 | 104.24 | 0.072 | |
| Lumbar pain | Absence | 47 | 14 | 1.00 | Reference | 1.00 | Reference | ||||
| Presence | 6 | 1 | 0.56 | 0.06 | 5.05 | 0.605 | 2.32 | 0.15 | 35.66 | 0.545 | |
| Lymphocyte count | 2.2- | 13 | 9 | 1.00 | Reference | 1.00 | Reference | ||||
| 416- | 13 | 2 | 0.22 | 0.04 | 1.23 | 0.085 | 0.03 | 1.90 | 1.23 | 0.170 | |
| 634.5- | 13 | 3 | 0.33 | 0.07 | 1.52 | 0.156 | 0.12 | 4.25 | 1.52 | 0.702 | |
| 915.2- | 14 | 1 | 0.10 | 0.01 | 0.93 | 0.043 | 0.02 | 2.49 | 0.93 | 0.220 | |
| Platelet count | 2.9- | 13 | 8 | 1.00 | Reference | 1.00 | Reference | ||||
| 15.3- | 14 | 4 | 0.46 | 0.11 | 1.92 | 0.289 | 0.40 | 0.07 | 2.25 | 0.300 | |
| 23.3- | 13 | 3 | 0.19 | 0.04 | 0.83 | 0.027 | 0.39 | 0.07 | 2.16 | 0.027 | |
| 32.1- | 13 | 0 | |||||||||
| CRP | 0.21- | 14 | 3 | 1.00 | Reference | 1.00 | Reference | ||||
| 2.58- | 12 | 1 | 0.39 | 0.04 | 4.25 | 0.439 | 0.73 | 0.05 | 10.59 | 0.820 | |
| 5.23- | 13 | 3 | 1.08 | 0.18 | 6.32 | 0.935 | 1.81 | 0.23 | 14.38 | 0.575 | |
| 8.97- | 14 | 8 | 2.67 | 0.58 | 12.19 | 0.206 | 3.18 | 0.49 | 20.81 | 0.227 | |
| Alb | 1.5- | 17 | 10 | 1.00 | Reference | 1.00 | Reference | ||||
| 2.55- | 17 | 3 | 0.30 | 0.07 | 1.29 | 0.105 | 0.85 | 0.14 | 5.31 | 0.866 | |
| 3.05- | 17 | 2 | 0.20 | 0.04 | 1.05 | 0.057 | 0.25 | 0.04 | 1.58 | 0.141 | |
| Missing values | 2 | 0 | – | – | – | – | – | – | |||
| BUN | 7- | 13 | 0 | 1.00 | Reference | 1.00 | Reference | ||||
| 13- | 9 | 1 | |||||||||
| 14- | 16 | 3 | 4.13 | 0.39 | 43.38 | 0.238 | 1.49 | 0.12 | 18.55 | 0.758 | |
| 21- | 15 | 11 | 16.13 | 1.88 | 138.47 | 0.011 | 6.61 | 0.59 | 73.41 | 0.124 | |
| Cr | 0.25- | 13 | 2 | 1.00 | Reference | 1.00 | Reference | ||||
| 0.54- | 14 | 1 | 0.46 | 0.0 | 5.7 | 0.550 | 0.15 | 0.0 | 2.8 | 0.201 | |
| 0.63- | 10 | 6 | 3.90 | 0.6 | 23.6 | 0.138 | 0.77 | 0.1 | 8.1 | 0.829 | |
| 0.87- | 16 | 6 | 2.44 | 0.4 | 14.2 | 0.321 | 0.57 | 0.1 | 5.2 | 0.618 | |
| GOT | 13- | 17 | 2 | 1.00 | Reference | 1.00 | Reference | ||||
| 29- | 18 | 4 | 1.89 | 0.31 | 11.68 | 0.494 | 2.08 | 0.28 | 15.29 | 0.474 | |
| 41- | 18 | 8 | 3.78 | 0.70 | 20.38 | 0.122 | 4.11 | 0.49 | 34.33 | 0.192 | |
| Missing values | 0 | 1 | – | – | – | – | – | – | |||
| GPT | 3- | 14 | 3 | 1.00 | Reference | 1.00 | Reference | ||||
| 17- | 20 | 2 | 0.47 | 0.07 | 3.17 | 0.435 | 0.23 | 0.03 | 1.96 | 0.180 | |
| 30- | 19 | 9 | 2.21 | 0.50 | 9.69 | 0.293 | 3.52 | 0.37 | 33.68 | 0.274 | |
| Missing values | 0 | 1 | – | – | – | – | – | – | |||
| LDH | 125- | 17 | 4 | 1.00 | Reference | 1.00 | Reference | ||||
| 205- | 18 | 1 | 0.24 | 0.02 | 2.33 | 0.217 | 0.11 | 0.01 | 1.31 | 0.081 | |
| 261- | 18 | 9 | 2.13 | 0.55 | 8.21 | 0.274 | 0.79 | 0.12 | 5.11 | 0.807 | |
| Missing values | 0 | 1 | – | – | – | – | – | – | |||
*: Adjusted for age and presence/absence of ARDS. Odds ratios for age and presence/absence of ARDS were only adjusted for other factors mutually. †: Odds ratio for each increase in age group was obtained, when patients were divided into three groups by age.
**: Sensitive to all anti-tuberculosis agents.
***: Resistance to at least one anti-tuberculosis agent.
****: Resistance to two anti-tuberculosis agents.
ARDS: acute respiratory distress syndrome, PS: Performance Status, AFB: Acid-fast bacteria, BMI: body mass index, WBC: white blood cell, Alb: Albumin, CRP: C-reactive protein, Cr: creatinine, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase.
Relationships between clinical factors and the risk of death within three months of miliary tuberculosis diagnosis: multivariate analysis.
| Parameters | Survivors ( | Non-survivors ( | Adjusted odds ratio† | 95% Confidence interval | |||
|---|---|---|---|---|---|---|---|
| Lower limit | Upper limit | ||||||
| Age (years) | ≤72 | 13 | 0 | 15.5‡ | 1.79 | 134.57 | |
| 73–78 | 11 | 0 | |||||
| 79–85 | 15 | 6 | |||||
| ≥86 | 14 | 9 | |||||
| ARDS onset | Absence | 46 | 9 | 1.00 | Reference | ||
| Presence | 7 | 6 | 12 | 1 | 141 | 0.050 | |
| Consciousness disturbance | Absence | 48 | 12 | 1.00 | Reference | ||
| Presence | 5 | 3 | 81.53 | 1.26 | 5258.40 | 0.038 | |
| BUN | 7- | 13 | 0 | 5.71‡ | 1.13 | 28.77 | |
| 13- | 9 | 1 | |||||
| 14- | 16 | 3 | |||||
| 21- | 15 | 11 | |||||
†: Four variables in the table were selected with age, presence/absence of ARDS during the disease course, PS, presence/absence of consciousness disturbance, and presence/absence of liver disease as explanatory variables with a removal probability of 0.1 by backward elimination.
‡: For age and BUN levels, odds ratios for each increase in group were obtained. ARDS: acute respiratory distress syndrome.
Baseline characteristics of patients with miliary tuberculosis (n = 68).
| Parameters | Results | Parameters | Results |
|---|---|---|---|
| Number of patients | 68 | AFB-positive sputum: positive/total (%) | |
| Age, years (range) | 83 (27–93) | Smear | 49/68 (71%) |
| Sex: male/female | 18/50 | PCR | 50/66 (76%) |
| Smoking history: current/former/never | 0/10/56 | MGIT | 47/55 (85%) |
| Alcohol intake: presence/absence | 8/59 | Culture | 57/68 (84%) |
| Underlying disease | Culture of AFB in specimens: positive/total (%) | ||
| Heart disease | 15 (22%) | Urine | 8/31 (26%) |
| Diabetes | 18 (27%) | Gastric effusion | 5/9 (56%) |
| Dementia | 16 (24%) | Scrotal pus | 12/37 (32%) |
| Malignancy | 11 (16%) | Blood | 2/20 (10%) |
| Cerebrovascular disease | 12 (18%) | Cerebrospinal fluid | 0/8 (0%) |
| Renal disease | 7 (10%) | Bronchial lavage fluid | 4/8 (50%) |
| Liver disease | 7 (10%) | Pleural effusion | 6/12 (50%) |
| Connective tissue disease with steroid treatment | 9 (13%) | Ascites fluid | 0/0 (0%) |
| Aneurysm | 3 (4%) | Histopathological examination positive/total (%) | |
| Neuromuscular disease | 3 (4%) | Transbronchial biopsy | 6/8 (75%) |
| None | 11 (16%) | Bone marrow biopsy | 9/14 (64%) |
| ARDS onset | 13 (19%) | Body mass index (kg/m2) | 18.8 (12.6–26.5%) |
| Symptoms | The period from onset to hospitalization, days (range) | 37 (3–361) | |
| Fever (≥38 °C) | 51 (75%) | ||
| Cough | 19 (28%) | The period from hospitalization to anti-tuberculosis treatment, days (range) | 2 (0–9) |
| Sputum | 14 (21%) | ||
| Dyspnea | 20 (29%) | The period from onset to anti-tuberculosis treatment, days (range) | 41 (3–364) |
| Loss of appetite | 44 (65%) | ||
| General malaise | 45 (66%) | Length of hospital stay, days (range) | 102 (2–547) |
| Consciousness disturbance | 8 (12%) | ||
| Lumbar pain | 7 (10%) | ||
| PS (median) | 3 (1–4%) | ||
Data are presented as median (range) or number (%).
ARDS: acute respiratory distress syndrome; PS:performance status; AFB: acid-fast bacteria; BMI: body mass index.